Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02).
about
A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer.Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer.Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone.Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma.Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy.Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure patternLow-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma.Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma.Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer.Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer.Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer.Perioperative outcomes of esophageal cancer surgery in a mid-volume institution in the era of centralization.Direct effects of chemoradiotherapy following esophagectomy.Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers.Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors.Guillain-Barré syndrome as an atypical manifestation of an esophageal carcinoma.Establishment and evaluation of four different types of patient-derived xenograft models.Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers.Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.Genetic prediction of long-term survival after neoadjuvant chemoradiation in locally advanced esophageal cancer.WNT and NOTCH signaling pathways as activators for epidermal growth factor receptor in esophageal squamous cell carcinoma
P2860
Q33841542-05B7E600-EACA-40CE-9C68-115906D31797Q33932460-FC44B718-35BA-4052-927F-F252D5B6E927Q33942343-AC019E64-0EE5-4787-BD21-B863E670FD2BQ34543795-06525DBF-470C-4130-A0B1-2C8EBBC6DD11Q34581435-DD480640-4BD5-4B24-ADFD-0D68A408457EQ34610991-09D06710-1AD5-47D4-8DA6-EDBD86715DE7Q35020568-554397FB-7609-43D4-B6E3-F47771D00D74Q35624456-01EFF630-A613-44B1-865C-B669CA5C50F1Q36055127-DFF3B3C0-FD1F-4B3E-B97A-1CA128D56EEEQ36150708-3A16FCCE-5B14-40F8-8C5C-7A1CB28F8F25Q36691859-7473E0E6-649D-4C08-A84F-8B367F430893Q37074909-9142ED61-5685-4630-9E74-F1C611179B1FQ37183749-71F462F2-E780-4B3F-A747-21FD2224FA4BQ37277133-7B5D0F0D-BD4D-43F2-9FA2-07B6A816C985Q37294511-002F9C4A-EDE8-46CF-BF26-A21774857E9EQ37433616-CBA25206-7238-4CD9-845B-BAC65EC31AA8Q37618080-96ECCEA5-D569-4A65-83B1-BCF879E52024Q38107463-77DDD2D2-B0A4-4253-8CAD-F141DD1AE69EQ38542060-126A6DA3-A58C-46C4-A615-1C5D63C01F0CQ39204464-60D1D771-2954-467D-BD5F-CC1D2EB74282Q39424590-A3FD3B34-F06B-4F74-AAAC-335FB6D0D828Q39582802-24088AF4-0FBC-4616-8828-305AF2575703Q39736167-6A605B45-0683-462B-9F28-56C74DA50925Q39933959-FE922E17-C74E-4A5C-97D8-DE5FB6405DAFQ41336093-6A6D2DD2-ADDB-435C-A08A-FA69D2254A63Q44563525-80F120C3-7BA6-4B08-8EF4-A4891BEEA856Q47140693-AC3E983B-49D9-4F27-9964-00F29170A17AQ47301455-98F07027-E01D-41FA-98BE-0AC913F385DFQ48244760-AA6FFACD-6ABE-47C8-A4AB-E77FB11A0BC9Q51512708-59BEC811-D274-4CFD-8285-FF1912EEC16DQ52875208-E436E00A-65A9-441C-A5AE-7B6D87DA48CDQ52882648-3A1FF6A4-6695-41E7-B7D9-5EFA2593E4E9Q57193567-A0E66FE4-AEA5-48CF-B399-BCB0BBFB1CB6
P2860
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02).
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Multicenter phase II trial of ...... hageal carcinoma (SAKK 75/02).
@en
Multicenter phase II trial of ...... advanced esophageal carcinoma
@nl
type
label
Multicenter phase II trial of ...... hageal carcinoma (SAKK 75/02).
@en
Multicenter phase II trial of ...... advanced esophageal carcinoma
@nl
prefLabel
Multicenter phase II trial of ...... hageal carcinoma (SAKK 75/02).
@en
Multicenter phase II trial of ...... advanced esophageal carcinoma
@nl
P2093
P2860
P921
P356
P1433
P1476
Multicenter phase II trial of ...... hageal carcinoma (SAKK 75/02).
@en
P2093
A Schnider
B C Pestalozzi
J C Schuller
L Terraciano
R von Moos
P2860
P304
P356
10.1093/ANNONC/MDP045
P577
2009-05-22T00:00:00Z